6. パーキンソン病
[臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
60 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03903549
(ClinicalTrials.gov)
November 1, 20203/4/2019Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy VolunteersA Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)Parkinson DiseaseDrug: [18F]P17-059Five Eleven Pharma, Inc.NULLNot yet recruiting45 Years90 YearsAll26Phase 1United States
2ChiCTR2000037856
2020-10-012020-09-02Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA) Parkinson's DiseaseGold Standard:DAT-PET and 18F-FDG PET ;Index test:a-synuclein protein misfolding cyclic amplification;Huashan Hospital Affiliated to Fudan UniversityNULLRecruiting5075BothTarget condition:150;Difficult condition:76China
3ChiCTR2000036137
2020-10-012020-08-21Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's diseaseClinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease Parkinson’s diseaseGold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging;Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong UniversityNULLPendingBothTarget condition:50;Difficult condition:0China
4NCT04265209
(ClinicalTrials.gov)
May 20206/2/2020[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorNon-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.Parkinson Disease;Essential TremorDrug: SPECT;Drug: PETZionexaNULLNot yet recruiting35 Years80 YearsAll112Phase 3NULL
5NCT04459052
(ClinicalTrials.gov)
April 30, 202026/6/2020FDOPA PET and Nutritional Support in Parkinson's DiseasePhase II: Physiological Effects of Nutritional Support in Patients With Parkinson's DiseaseParkinson Disease;Idiopathic Parkinson DiseaseDietary Supplement: N acetyl cysteine;Drug: [F-18] Fluorodopa Positron Emission TomographyThomas Jefferson UniversityNULLActive, not recruiting30 YearsN/AAll50Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04175132
(ClinicalTrials.gov)
November 12, 201912/11/2019Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's DiseaseHealthy;Parkinson DiseaseDrug: foligluraxH. Lundbeck A/SNULLTerminated50 Years70 YearsAll6Phase 1Sweden
7NCT04062526
(ClinicalTrials.gov)
August 14, 201914/8/2019Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CTEvaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)Parkinson Disease;Healthy VolunteerDrug: [18F]NOSUniversity of PennsylvaniaNULLRecruiting18 Years75 YearsAll30Early Phase 1United States
8JPRN-UMIN000036952
2019/06/0404/06/2019A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.18F-FDOPA, 11C-Raclopride PETNagoya City Rehabilitation AgencyNULLRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
9JPRN-UMIN000036908
2019/05/3131/05/2019A dementia study by 11C-PiB, 18F-FDG PETA dementia study by 11C-PiB, 18F-FDG PET - A dementia study by 11C-PiB, 18F-FDG PET mild cognitive impairment, Alzheimer's disease, dementia with Lewy bodies, cerebrovascular dementia, frontotemporal degeneration, progressive supranuclear palsy, corticobasal degeneration, Parkinson's disease with dementia, other neurodegenerative diseases, normal pressure hydrocephalus, hypoxic encephalopathy, brain tumor, brain injury etc.11C-PiB, 18F-FDG PETNagoya City Rehabilitation AgencyNULLRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
10EUCTR2019-000247-27-FR
(EUCTR)
02/05/201905/03/2019Study to demonstrate an at least equivalent performance of a new test in brain imaging test compared to the reference examination to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. - DATTEP Patients suffering from an essential tremor or with Parkinson's disease.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Classification code 10015496;Term: Essential tremor;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Trade Name: DaTSCAN 74 MBq/ml solution for injection
Product Code: [18F] LBT-999
ZIONEXANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
112Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11JPRN-jRCTs051180214
29/03/201927/03/2019The usefulness of flutemetamol for diagnostic imaging of neurogenerative diseaseThe usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease Alzheimer's disease,Dementia with Lewy Bodies,Parkinson's syndrome,Frontotemporal lober degeneration
Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's syndrome, Frontotemporal lober degeneration, Parkinson's disease, Mild cognitive impairment, Non-Alzheimer's disease, Progressive aphasia, Neurodegenerative disease, Cerebral corticobasal degeneration, Progressive supranuclear palsy
Amyloid PET: Given the flutemetamol (3mL) intravenously
FDG-PET:Given the FDG scanR (3mL) intravenously
Itoh YoshiakiNULLRecruitingAges 20 and overN/ABoth100N/AJapan
12NCT03826134
(ClinicalTrials.gov)
January 17, 201930/1/2019A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy SubjectsInterventional, Phase I, Open-label, First in Human, Single-center Positron Emission Tomography (PET) Study Investigating Test-retest Properties of [11C]-PXT012253 as a Radiotracer in Healthy SubjectsParkinson DiseaseDrug: [11C]PXT012253H. Lundbeck A/SNULLCompleted20 Years50 YearsAll7Early Phase 1Sweden
13NCT03230526
(ClinicalTrials.gov)
April 20, 201818/7/2017Identification of a Biomarker Predictive of Evolution of Parkinson DiseaseBrain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?Parkinson DiseaseDrug: [18F]DPA-714 PET scanNantes University HospitalNULLRecruiting40 Years67 YearsAll64Phase 2France
14EUCTR2018-000405-23-FI
(EUCTR)
27/03/201821/02/2018Postitron emission tomography imaging of neuroinflammation in Parkinson´s diseaseIn vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD) - PRI-PD Parkinson´s disease
MedDRA version: 20.0;Level: LLT;Classification code 10034007;Term: Parkinson's disease NOS;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Product Code: [11C]SMW139
Juha Rinne / PET CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
14Phase 2Finland
15NCT03457493
(ClinicalTrials.gov)
March 22, 201823/2/2018TSPO-PET for Neuroinflammation in Parkinson's DiseaseUAB Neuroinflammation in Parkinson's Disease - TSPO-PET SubstudyParkinson DiseaseDrug: DPA-714-PET/MRIUniversity of Alabama at BirminghamNULLRecruiting30 YearsN/AAll20Phase 1;Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16JPRN-UMIN000030084
2017/12/0101/12/2017Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease neuroinflammatory disorder, Parkinson's disease, Brain tumor[18F]GE180 is injected intravenously as 3-4 MBq/Kg. PET is dynamically scanned for 90 minutes.

Carbidopa 150mg is administrated orally 1hr before scan.[18F]FDOPA is injected intravenously as 3-4 MBq/Kg. Dynamic PET is scanned for 90 minutes.

[18F]FLT is injected intravenously as 3-4 MBq/Kg. Statical PET is scanned after 60 minutes
Kyoto UniversityNULLComplete: follow-up complete50years-oldNot applicableMale and Female12Phase 1;Phase 2Japan
17NCT03555292
(ClinicalTrials.gov)
July 12, 201724/4/201811C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia SyndromesSafety and Diagnostic Performance of 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia SyndromesParkinson DiseaseDrug: 11C-PiBOriental Neurosurgery Evidence-Based-Study TeamNULLRecruiting18 YearsN/AAll200Phase 2China
18NCT03042416
(ClinicalTrials.gov)
June 29, 20171/2/201718F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety18F-DOPA PET Imaging: an Evaluation of Biodistribution and SafetyCongenital Hyperinsulinism;Neuroblastoma;Neuroendocrine Tumors;Parkinson Disease;Brain GliomaDrug: 18F-DOPAUniversity of AlbertaAlberta Health ServicesActive, not recruitingN/AN/AAll400Phase 3Canada
19NCT03973502
(ClinicalTrials.gov)
June 12, 201730/5/2019Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PDApplication of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.Hepatitis C;Hepatitis B;Parkinson DiseaseDrug: 18F-DOPA PETNational Taiwan University HospitalNULLRecruiting20 YearsN/AAll230N/ATaiwan
20ChiCTR-DDD-16009569
2017-01-012016-10-24Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imagingDifferential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging Parkinson's DiseaseGold Standard:;Index test:;Renji hospital, School of Medicine, Shanghai Jiao Tong UniversityNULLPending2080BothTarget condition:0;Difficult condition:0China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21JPRN-UMIN000025638
2016/11/0116/01/2017Adenosine A2A receptors in Parkinson's disease Parkinson's disease11C-preladenant-PET scanningTokyo Metropolitan Institute of GerontologyNULLComplete: follow-up complete40years-old89years-oldMale and Female40Not selectedJapan
22NCT02538315
(ClinicalTrials.gov)
October 201625/8/2015Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease PatientsUsing 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease PatientsParkinson`s DiseaseDrug: [18F]FDOPA PET/CTUniversity of SaskatchewanUniversity of ManitobaRecruiting18 YearsN/AAll30N/ACanada
23EUCTR2014-001014-25-ES
(EUCTR)
20/07/201615/07/2016Brain amyloid beta burden as per florbetaben PETBrain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease Parkinson's Disease
MedDRA version: 19.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Neuraceq
Product Name: Neuraceq
INN or Proposed INN: FLORBETABEN (18F)
Fundació Clínic per la Recerca BiomèdicaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 4Spain
24EUCTR2015-004129-15-ES
(EUCTR)
07/03/201624/02/2016Subjects participating in a Parkinson Disease cohort are offered to undergo a PET imaging scan requiring an intravenous diagnostic drug (florbetaben) with the aim of identifying markers of disease progressionEvaluation of [18F] florbetaben in subjects participating in the Parkinson?s Progression Markers Initiative (PPMI) Protocol Parkinson's Disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Neuraceq
Product Name: 18F florbetaben
INN or Proposed INN: FLORBETABEN (18F)
Institute for Neurodegenerative DisordersNULLNot RecruitingFemale: yes
Male: yes
Phase 2Spain
25JPRN-jRCTs041180070
04/11/201507/03/2019Trerief Impact in PD PET StudyRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - TIPPS Parkinson's disease
Parkinson's disease;D010300
[1] Zonisamide treatment group
Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
[2] Zonisamide non-treatment group
Only levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.
Ouchi YasuomiNULLNot RecruitingNot applicable< 80age oldBoth20N/AJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2015-003045-26-SE
(EUCTR)
23/10/201515/09/2015Study of Dopamine Transporters (signal substance in central nervous system)in patients with early signs of Parkinson´s disease.[18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease. Patients with newly clinically diagnosed untreated idiopathic parkinsonism
MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: [18F]FE-PE2I
INN or Proposed INN: [18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Trade Name: DaTSCAN
INN or Proposed INN: IOFLUPANE (123I)
Product Name: 15O H2O
INN or Proposed INN: [15O]H2O
Umeå University HospitalNULLNot RecruitingFemale: yes
Male: yes
105Phase 2Sweden
27NCT02933372
(ClinicalTrials.gov)
October 5, 20156/4/2016Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3Parkinson's DiseaseDrug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by InvestigatorUniversity of MichiganNULLCompleted45 YearsN/AAll25Phase 2NULL
28JPRN-UMIN000019524
2015/10/0128/10/2015Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) imagesRandomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images - Trerief Impact in PD PET Study (TIPPS) Parkinson's DiseaseZonisamide treatment group:

Zonisamide (25 mg) once daily in addition to levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) one or two tablets per day in case of developing wearing off phenomenon, 2) change of dose and/or administration of levodopa/DCI, and 3) addition of other anti-parkinsonian drugs due to exacerbation of symptoms.
Zonisamide non-treatment group:

Only Levodopa/DCI with fixed dosage and administration.
Note that after one-year fixed protocol period, the followings are allowed; 1) change of dose and/or administration of levodopa/DCI and 2) addition of other anti-parkinsonian drugs except for zonisamide due to exacerbation of symptoms.
Hamamatsu University School of MedicineNULLComplete: follow-up completeNot applicable80years-oldMale and Female20Not applicableJapan
29NCT02393027
(ClinicalTrials.gov)
March 20156/3/2015Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999Idiopathic Parkinson DiseaseDrug: [18F] LBT-999 PETUniversity Hospital, ToursNULLTerminated45 Years75 YearsAll16Early Phase 1France
30JPRN-UMIN000014709
2014/07/0101/08/2014Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2IStudy on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I - DAT PET with [C-11]PE2I in PD and related disorders Patients of Parkinson's disease and related disordersThe dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.Tokyo Metropolitan Institute of GerontologyNULLComplete: follow-up complete18years-oldNot applicableMale and Female200Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT02064166
(ClinicalTrials.gov)
February 201413/2/2014Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System AtrophyParkinson Disease;Multiple System AtrophyDrug: Intranasal InsulinPeter NovakNULLCompleted18 YearsN/AAll15Phase 2United States
32NCT02103894
(ClinicalTrials.gov)
February 201412/2/2014Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsEvaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy SubjectsAlzheimer's Disease (AD);Parkinson's Disease (PD);Chronic Traumatic Encephalopathy (CTE);Progressive Supranuclear Palsy (PSP);Frontal Temporal Dementia (FTD);Pick's Disease;TauopathiesDrug: [18F]T807 ([18F]MNI-777)Molecular NeuroImagingInstitute for Neurodegenerative DisordersCompleted18 Years85 YearsBoth16Phase 1United States
33NCT02012595
(ClinicalTrials.gov)
October 201326/11/2013[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons DiseaseParkinson's DiseaseOther: [11C]donepezil PETPer BorghammerLundbeck Foundation;Jascha Fonden;Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons SygdomCompleted40 Years80 YearsBoth24N/ADenmark
34JPRN-UMIN000011111
2013/07/1615/07/2013Spinal blood flow and metabolism in neurological diseases motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophyPET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesNULLRecruiting20years-oldNot applicableMale and Female70Not applicableJapan
35NCT01877538
(ClinicalTrials.gov)
May 201311/6/2013Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System[11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy AdultsParkinson's DiseaseOther: [11C]donepezil PETPer BorghammerLundbeck FoundationCompleted45 Years75 YearsMale7Denmark
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT02059733
(ClinicalTrials.gov)
February 20137/2/2014Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and ParkinsonismDeveloping a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PETParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNULLCompleted20 Years80 YearsAll72Phase 2Taiwan
37EUCTR2011-004803-19-FI
(EUCTR)
16/08/201216/05/2012PET study in PD patientsA Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AZD3241 Extended release tablets 25 mg
Product Code: AZD3241
Product Name: AZD3241 Extended release tablets 100 mg
Product Code: AZD3241
Product Name: [11C]PBR28
Product Code: [11C]PBR28
Product Name: [18F]FE-PE2I
Product Code: [18F]FE-PE2I
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
24Phase 2AFinland;Sweden
38NCT02319382
(ClinicalTrials.gov)
June 201218/11/2014Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PETHigh Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714Parkinson's Disease With LRRK2 Mutation;Healthy Controls;Parkinson's Disease Without LRRK2 MutationRadiation: PET with the tracer 18F-DPA-714;Radiation: PET with the tracer 11C-PE2I;Other: MRIAssistance Publique - Hôpitaux de ParisFrance Parkinson AssociationRecruiting18 YearsN/ABoth46N/AFrance
39NCT01550484
(ClinicalTrials.gov)
April 20126/3/2012A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement DisordersAn Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain DiagnosisParkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's DiseaseDrug: 18F-AV-133Avid RadiopharmaceuticalsNULLCompleted40 YearsN/AAll170Phase 2;Phase 3United States;Australia
40NCT01527695
(ClinicalTrials.gov)
April 201222/12/2011PET Study in Parkinson's Disease PatientsA Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's DiseaseParkinson's DiseaseDrug: ER tablet 25 mg AZD3241;Drug: ER tablet 100 mg AZD3241;Drug: Placebo for AZD3241 25 mg;Drug: Placebo for AZD3241 100 mgAstraZenecaNULLCompleted45 Years75 YearsBoth24Phase 2Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT02039024
(ClinicalTrials.gov)
March 201215/1/2014Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETImaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETParkinson's DiseaseDrug: 18F- DTBZChang Gung Memorial HospitalNational Science Council, TaiwanCompleted20 Years80 YearsBoth18Phase 2Taiwan
42EUCTR2011-004803-19-SE
(EUCTR)
22/02/201216/12/2011PET study in PD patientsA Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease Parkinson's Disease; Microglia activation as measured by [11C]PBR28 binding to TSPO
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AZD3241 Extended release tablets 25 mg
Product Code: AZD3241
Product Name: AZD3241 Extended release tablets 100 mg
Product Code: AZD3241
Product Name: [11C]PBR28
Product Code: [11C]PBR28
Product Name: [18F]FE-PE2I
Product Code: [18F]FE-PE2I
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
24Phase 2AFinland;Sweden
43NCT01461109
(ClinicalTrials.gov)
August 201127/9/2011Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy ControlsEvaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy SubjectsParkinson Disease;Alzheimer DiseaseDrug: [18F] CFPyPBInstitute for Neurodegenerative DisordersNULLCompleted18 Years90 YearsBoth4Phase 1United States
44NCT01759888
(ClinicalTrials.gov)
August 20111/1/2013Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismFrom Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNational Science Council, TaiwanCompleted20 Years80 YearsBoth49Phase 2Taiwan
45NCT01462708
(ClinicalTrials.gov)
May 20118/6/2011Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy SubjectsEvaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy ControlsParkinson DiseaseDrug: [18F]MK-9470Institute for Neurodegenerative DisordersNULLCompleted18 Years90 YearsBoth16Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01283347
(ClinicalTrials.gov)
May 201011/1/201118F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingPhase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNULLCompleted50 Years80 YearsBoth100Phase 2Taiwan
47NCT01503944
(ClinicalTrials.gov)
March 201014/7/2010A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly VolunteersDementia With Lewy Bodies;Alzheimer's Disease;Parkinson's DiseaseDrug: 18F-AV-133;Drug: 18F-AV-45Avid RadiopharmaceuticalsNULLCompleted50 YearsN/ABoth30Phase 1;Phase 2United States
48NCT01028209
(ClinicalTrials.gov)
November 20098/12/2009Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological ConditionsAlzheimer Disease;Parkinson Disease;Multiple SclerosisDrug: [18F] PBR06Institute for Neurodegenerative DisordersNULLTerminated18 YearsN/AAll12Phase 1United States
49NCT00970333
(ClinicalTrials.gov)
August 200931/8/2009Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological ConditionsEvaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological ConditionsAlzheimer Disease;Parkinson Disease;Multiple SclerosisDrug: [18F]-FEPPAInstitute for Neurodegenerative DisordersNULLCompleted18 YearsN/ABoth3Phase 1United States
50NCT00870974
(ClinicalTrials.gov)
March 200926/3/2009A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsEvaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric ConditionsParkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive ImpairmentDrug: [18F]FPEBInstitute for Neurodegenerative DisordersNULLCompleted18 Years85 YearsAll48Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT01039090
(ClinicalTrials.gov)
February 200922/12/2009Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's DiseaseProspective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan StudyParkinsons's DiseaseDrug: Continuous Apomorphine infusion;Drug: Usual dopaminergic per os treatmentRennes University HospitalNULLCompleted18 YearsN/AAll21Phase 3France
52NCT00857532
(ClinicalTrials.gov)
January 20095/3/2009Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease PatientsA Phase 2 Trial of Florbetapir F18 PET Imaging of ß-amyloid in Parkinson's Disease Patients With Cognitive ImpairmentParkinson's DiseaseDrug: florbetapir F 18Avid RadiopharmaceuticalsNational Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)Completed60 YearsN/AAll31Phase 2United States
53NCT00562198
(ClinicalTrials.gov)
January 200819/11/2007PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingEffects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an Open, Randomised, Active-Controlled,Two-Period Crossover Study.Parkinson´s DiseaseDrug: entacapone and carbidopa;Drug: Sinemet 200mg/50mgOrion Corporation, Orion PharmaNULLTerminated45 Years80 YearsBoth16Phase 2Finland
54NCT00468078
(ClinicalTrials.gov)
November 200630/4/2007Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor PatientsThe Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor PatientsParkinson's DiseaseProcedure: PET/CT;Drug: F-18 FPCITAsan Medical CenterNULLCompleted40 YearsN/ABoth78Phase 3Korea, Republic of
55EUCTR2004-004139-74-DK
(EUCTR)
20/04/200522/03/2005Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/AParkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A Parkinson's DiseaseTrade Name: Ebixa
Product Name: Ebixa
INN or Proposed INN: memantine
Neurologisk afdeling FNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2Denmark
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT00375778
(ClinicalTrials.gov)
April 200512/9/2006Parkinson's Disease Evaluated by PET and the Effect of MemantineParkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist MemantineParkinson's DiseaseDrug: memantine (drug)University of AarhusLundbeck FoundationCompleted50 Years70 YearsBoth12N/ADenmark
57NCT00153972
(ClinicalTrials.gov)
February 20057/9/2005Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's DiseaseDopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's DiseaseParkinson's DiseaseDrug: Cabergoline;Drug: LevodopaTechnische Universität DresdenPfizerCompleted40 Years85 YearsBoth39Phase 4Germany
58NCT00220272
(ClinicalTrials.gov)
January 200416/9/2005Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's DiseaseA Phase II, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients With Early Parkinson's DiseaseParkinson DiseaseDrug: SR57667BSanofiNULLCompleted35 YearsN/ABoth183Phase 2Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom
59NCT01044992
(ClinicalTrials.gov)
May 20026/1/2010Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) StudyMotor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic ChallengeMultisystemic AtrophyRadiation: H215O PET;Drug: LevodopaUniversity Hospital, ToulouseNULLCompleted40 Years75 YearsBoth38N/AFrance
60NCT00032812
(ClinicalTrials.gov)
March 20023/4/2002The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's DiseaseMotor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEGParkinson Disease;HealthyDrug: RacloprideNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth64N/AUnited States